BPC-157 is a synthetic linear pentadecapeptide, Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, with free N- and C-termini and no further modifications. The sequence was described as a partial sequence of a larger protein isolated from human gastric juice, and the peptide appears in the literature under the research codes PL 14736, PL-10 and PLD-116.

At the cellular level, BPC-157 has been reported to activate a Src–caveolin-1–endothelial nitric oxide synthase (eNOS) pathway in cultured endothelial cells, to increase VEGFR2 expression in endothelial cells, and to up-regulate growth hormone receptor expression in cultured fibroblasts. Its interaction with the nitric oxide system has been reviewed extensively. No dedicated receptor has been identified to date.

Research citing BPC-157 spans endothelial cell signaling, nitric oxide pathway pharmacology, fibroblast culture models, cell-migration assays, and analytical chemistry, including LC-MS characterization of its in vitro metabolism. The peptide has been reported to remain stable in acidic aqueous media, an unusual property among short linear peptides.

Research use only. This material is sold for in-vitro laboratory research and development purposes exclusively. It is not a drug, food, or dietary supplement, has not been evaluated by the FDA, and must not be used in humans or animals.